STRONGBRIDGE BIOPHARMA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of SBBP and Encourages Investors to Contact the Firm
24 mai 2021 12h43 HE
|
Bragar Eagel & Squire
NEW YORK, May 24, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...
Strongbridge Biopharma plc Provides Updates on KEVEYIS® Launch and Recent Business Highlights, and Reports Second Quarter 2017 Financial Results
07 août 2017 07h00 HE
|
Strongbridge Biopharma plc
~ Launched KEVEYIS® (dichlorphenamide) to U.S. Primary Periodic Paralysis Community, Established Strongbridge CareConnection Patient Services and Support Program, and Mobilized 12-Person...
Strongbridge Biopharma plc Completes Target Enrollment of 90 Patients in the Phase 3 SONICS Study Evaluating RECORLEV™ (levoketoconazole) in Endogenous Cushing’s Syndrome
27 juin 2017 07h30 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., June 27, 2017 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and...